

Prof.Dr. Deniz YAMAÇ

Ankara'da doğdu ve TED Ankara Koleji'nde orta ve lise eğitimini tamamladı. Ankara Tıp Fakültesi'nden mezun olduktan sonra Gazi Üniversitesi Tıp Fakültesi'nde iç hastalıkları ve tıbbi onkoloji ihtisaslarını yaptı. Bir yıl Arkansas /ABD' de kanser merkezinde çalıştı. Gazi Üniversitesi Tıp Fakültesi'nde 1995 ten itibaren öğretim üyesi olarak görev aldı ve 2011 yılında professor kadrosunda iken emekliye ayrılarak Ankara Güven Hastanesi ailesine katıldı. Meme kanseri, baş-boyun kanseri başta olmak üzere tüm kanser tipleri ile ilgilenmektedir. Kanserde destek tedavileri ve iletişim konularında da ayrıca eğitimler vermektedir. Çok sayıda yurt dışı ve yurt içi yayını vardır. Özel yaşamında spor ve müzikle uğraşmaktadır. Meme kanseri ile yaşayan kadınların oluşturduğu "Farkındalık Korosu" nun da kuruluşunda bulunmuştur ve çalışmalarına katılmaktadır. Evlidir ve iki oğlu vardır.

YAYINLAR

1. Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay. Manguoğlu E, Güran S, Yamaç D, Simşek M, Akdeniz S, Colak T, Gülkesen H, Lüleci G. Cancer Invest. 2011 Jan;29(1):73-7. Epub 2010 Oct 5.
2. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients. Manguoğlu E, Güran S, Yamaç D, Colak T, Simşek M, Baykara M, Akaydın M, Lüleci G. Cancer Genet Cytogenet. 2010 Dec;203(2):230-7.
3. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer. Kaya AO, Coskun U, Buyukberber S, Benekli M, Tekin E, Cifter C, Ozturk B, Yildiz R, Yaman E, Uner A, Yamac D. J BUON. 2010 Apr-Jun;15(2):248-54.
4. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A. J Cancer Res Clin Oncol. 2010 Oct; 136(10):1471-6. Epub 2010 Feb 13.
5. Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish Oncology Group". Icli F, Akbulut H, Yalcin B, Ozdemir F, Isikdogan A, Hayran M, Unsal D, Coskun S, Buyukcelik A, Yamac D. Med Oncol. 2011 Mar;28(1):112-20. Epub 2010 Jan 7.
6. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, Ozturk B, Yaman E, Benekli M. Cancer Invest. 2010 Jan;28(1):33-7.
7. Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma. Coşkun U, Akyürek N, Dursun A, Yamaç D. J Surg Res. 2010 Nov;164(1):110-5. Epub 2009 May 3.
8. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY,

Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S. Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):683-6.

9. Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A; Anatolian Society of Medical Oncology (ASMO). Med Oncol. 2010 Mar;27(1):152-7. Epub 2009 Feb 26.

10. Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. Yaman E, Buyukberber S, Uner A, Coskun U, Yamac D, Ozturk B, Kaya AO, Yildiz R, Benekli M; Anatolian Society of Medical Oncology (ASMO). Tumori. 2008 Sep-Oct;94(5):674-80.

11. Coexistence of gastrointestinal stromal tumor (GIST) of the rectum and adenocarcinoma of the prostate in a patient with familial GIST. Yaman E, Coskun U, Benekli M, Sozen S, Yamac D, Buyukberber S, Ozturk B, Kaya AO, Yildiz R, Tezel E. Onkologie. 2008 Dec;31(12):697-9. Epub 2008 Nov 4.

12. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Adv Ther. 2008 Aug;25(8):801-9.

13. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Yaman E, Buyukberber S, Uner A, Coskun U, Akmansu M, Benekli M, Yamac D, Ozturk B, Kaya AO, Yildiz R, Ozkan S, Gunel N. Onkologie. 2008 Jun;31(6):309-13. Epub 2008 May 27.

14. Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens. Coskun U, Kaya AO, Buyukberber S, Benekli M, Uner A, Dikilitas M, Ozturk B, Yildiz R, Ozkan S, Yaman E, Yamac D. Med Oncol. 2008;25(2):133-6. Epub 2007 Sep 14.

15. Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Yamac D, Ayyildiz T, Coşkun U, Akyürek N, Dursun A, Seckin S, Koybasioglu F. Pathol Res Pract. 2008;204(8):527-36. Epub 2008 May 6.

16. Ultrastructural damage in lung tissues in rats treated with doxorubicin and paclitaxel. Take G, Yamaç D, Ozoğul C, Erdogan D. Adv Ther. 2008 Feb;25(2):115-22.

17. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Benekli M, Yildiz R, Uner A, Er O, Yamac D, Alkis N, Coskun U, Camci C, Buyukberber S. Oncology. 2007;72(5-6):308-13. Epub 2008 Jan 14.

18. The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma. Ozturk B, Buyukberber S, Akmansu M, Coskun U, Yamac D, Uner A, Yaman E, Yildiz R, Kaya AO, Bora H, Unsal D, Pak Y, Benekli M. Med Oncol. 2008;25(3):269-73. Epub 2007 Dec 15.

19. Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma? Ozdemir A, Voyvoda NK, Gultekin S, Tuncbilek I, Dursun A, Yamac D. *Clin Breast Cancer*. 2007 Oct;7(10):791-5.
20. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Yaman E, Uner A, Er O, Coskun U, Buyukberber S, Dikilitas M, Polat M, Yamac D, Kaya AO, Yildiz R, Ozturk B, Benekli M. *Med Oncol*. 2007;24(4):431-5.
21. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S. *Neoplasma*. 2007;54(4):348-52.
22. Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin. Yamaç D, Elmas C, Ozoğul C, Keskil Z, Dursun A. *Ultrastruct Pathol*. 2006 Jan-Feb;30(1):103-10.
23. Prognostic importance of COX-2 expression in patients with colorectal cancer. Yamac D, Celenkoglu G, Coskun U, Akyurek N, Akcali Z, Dursun A, Koybasioglu F. *Pathol Res Pract*. 2005;201(7):497-502.
24. A patient with occult breast cancer presenting with an axillary lymph node metastasis and a synchronous contralateral breast cancer. Yirmibeşoğlu E, Tekin E, Memiş L, Yamaç D, Taneri F, Erkal HS. *Breast*. 2005 Apr;14(2):157-62.
25. Polymyositis and hepatitis concurrent with breast cancer. Yamac D, Gunel N, Goker B, Coskun U, Erdem O, Akyol G, Ozenirler S. *Med Princ Pract*. 2004 May-Jun;13(3):171-5.
26. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer. Coskun U, Gunel N, Onuk E, Yilmaz E, Bayram O, Yamac D, Cihan A, Ucan B, Yildirim Y, Celenkoglu G, Ozkan S. *Neoplasma*. 2003;50(3):210-6.
27. Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Akyürek N, Akyol G, Dursun A, Yamaç D, Günel N. *Pathol Res Pract*. 2002;198(10):665-74.
28. Prognostic implication of nm23-H1 expression in colorectal carcinomas. Dursun A, Akyürek N, Günel N, Yamaç D. *Pathology*. 2002 Oct;34(5):427-32.
29. Prognostic importance of tumor angiogenesis in breast carcinoma with adjuvant chemotherapy. Gunel N, Akcali Z, Coskun U, Akyol G, Yamac D, Yenidünya S. *Pathol Res Pract*. 2002;198(1):7-12.
30. Effect of cisplatin on skin metastasis in breast cancer patients. Coşkun U, Gunel N, Yamac D, Altinova AE. *Onkologie*. 2001 Dec;24(6):576-9.
31. The clinicopathologic characteristics of colorectal cancer in patients under 50 years of age: experience of an oncology center. Günel N, Yamac D, Akcali Z, Taneri F, Oguz M. *Tumori*. 2001 Mar-Apr;87(2):74-7.
32. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Günel N, Akçali Z, Yamaç D, Onuk E, Yilmaz E, Bayram O, Tekin E, Coşkun U. *Tumori*. 2000 Jul-Aug;86(4):283-5.